Paying twice: Questions over high cost of cystic fibrosis drug developed with charitable funding

BMJ (Online)

Volumn 348, Issue , 2014, Pages

  Cohen, Deborah ^a   Raftery, James ^b  

^a BMJ ^*  (United Kingdom)

^b UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOPHENOLS; CYSTIC FIBROSIS; DRUG DISCOVERY; DRUG INDUSTRY; FOUNDATIONS; GREAT BRITAIN; HUMANS; QUINOLONES; RESEARCH SUPPORT AS TOPIC; UNITED STATES;

EID: 84894259985     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.g1445     Document Type: Article

References (18)

1. O'Sullivan BP, Orenstein DM, Milla CE. Pricing for orphan drugs. JAMA 2013;310:1343-4.
2. Food and Drug Administration. FDA approves Kalydeco to treat rare form of cystic fibrosis. Press release, 31 January 2012. www.fda.gov/NewsEvents/ Newsroom/PressAnnouncements/ucm289633.htm.
3. Venture philanthropy on the rise. CenterWatch Monthly 2007;14(8). www.themmrf.org/assets/about-the-mmrf/powerful-news/venture-philanthropy-on-the. pdf.
4. Institute of Medicine. Venture philanthropy strategies to support translational research: workshop summary. National Academy Press, 2009. www.ncbi.nlm.nih.gov/books/NBK45141.
5. McGrory B. Driven by loss, father inspires tireless pursuit of a cure. Boston Globe 2012 Feb 9. www.boston.com/news/local/massachusetts/articles/2012/ 02/09/joeys-long-legacy/?page=1.
6. Cystic Fibrosis Foundation. Annual report 2012. www.cff.org/ UploadedFiles/aboutCFFoundation/AnnualReport/2012-Annual-Report.pdf.
7. Werth B. A tale of two drugs. MIT Technology Review 2013 Oct 22. www.technologyreview.com/featuredstory/520441/a-tale-of-two-drugs.
8. Letter to Jeff Lieden, 9 July 2012. http://media.jsonline.com/documents/ CFletteruse.pdf.
9. Cystic Fibrosis sufferer denied "chance of life" drug by NHS. Telegraph 2012 Oct 28. www.telegraph.co.uk/health/healthnews/9639090/Cystic- Fibrosis-sufferer-denied-chanceof-life-drug-by-NHS.html.
10. Cystic fibrosis-quest for Kalydeco, 27 September 2012. www.facebook.com/QuestForKalydeco/posts/212081422256581.
11. Scottish Parliament. PEO1462: new treatment for cystic fibrosis. www.scottish.parliament.uk/GettingInvolved/Petitions/CFtreatment.
12. NHS Commissioning Board. Clinical commissioning policy: ivacaftor for cystic fibrosis. 2012. www.england.nhs.uk/wp-content/uploads/2013/04/a01-p-b. pdf.
13. Cystic fibrosis patients to get ivacaftor in Scotland. BBC News 2013 Jan 17.
14. Scottish Government. Consideration of new petition PE1462, 23 January 2013. www.scottish.parliament.uk/S4-PublicPetitionsCommittee/ General%20Documents/PE1462-B-Scottish-Government-30.01.13.pdf.
15. Vertex reviews corporate strategy and outlines key 2014 business priorities at the 32nd annual J.P. Morgan healthcare conference. Press release, 12 January 2014. www.marketwatch.com/story/vertex-reviews-corporate-strategy- and-outlines-key-2014-businesspriorities-at-the-32nd-annual-jp-morgan- healthcare-conference-2014-01-12.
16. FiercePharma. Kalydeco-Vertex Pharmaceuticals. 2013. www.fiercepharma. com/specialreports/kalydeco-top-15-drug-launch-superstars.
17. Centre for Drug Evaluation and Review. Summary review of regulatory action. 2012. www.accessdata.fda.gov/drugsatfda-docs/nda/2012/ 203188Orig1s000SumR.pdf.
18. Ivacaftor. Uncertain harm-benefit balance. Prescrire Int 2013;22:229-31.